Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity

Area of Science:

• Neuroscience
• Immunology
• Biochemistry

Background:

• Beta-amyloid (Aβ) peptides are central to Alzheimer's disease (AD) pathology.
• Complement system activation by Aβ contributes to neuroinflammation and neuronal damage in AD.
• The classical complement pathway is implicated in Aβ-mediated neurotoxicity.

Purpose of the Study:

• To investigate the protective role of C1-Inhibitor (C1-Inh) against Aβ-induced complement-mediated lysis of hippocampal cells.
• To identify and characterize compounds that inhibit the binding of C1q to Aβ.
• To evaluate the therapeutic potential of targeting the C1q-Aβ interaction in AD.

Main Methods:

• Cell culture of rat hippocampal neurons.
• Assessment of complement-dependent cell lysis.
• Screening of compound libraries for inhibitors of C1q-Aβ binding.
• Characterization of C1q binding sites using biochemical assays.

Main Results:

• C1-Inhibitor demonstrated protection of hippocampal cells against Aβ-induced complement lysis, confirming classical pathway involvement.
• Screening identified compounds that inhibit C1q binding to Aβ.
• C1q was found to have distinct binding sites for Aβ and antibodies.
• A selected compound successfully protected hippocampal cells from complement-dependent Aβ toxicity.

Conclusions:

• Complement activation by Aβ poses a significant threat to hippocampal cells in Alzheimer's disease.
• C1q is a key mediator of this deleterious complement pathway.
• Targeting the C1q-Aβ interaction with specific inhibitors represents a promising therapeutic strategy for AD.